Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Stomach Neoplasms 5Colorectal Neoplasms 3Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Neoplasms 1

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2durvalumab 2Specimen Handling 2Polymerase Chain Reaction 2Leucovorin 2Interleukin-2 2Imatinib Mesylate 2Gemcitabine 2Fluorouracil 2Doxorubicin 2Dasatinib 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2venetoclax 1vactosertib 1trametinib 1tazemetostat 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1palbociclib 1olaparib 1neratinib 1motexafin gadolinium 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × vactosertib × Gastrointestinal × Clear all
NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Case Comprehensive Cancer Center

Phase 1 Suspended
12 enrolled
GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡